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Previous research has focused on spray dried quaternary mixtures which due to the addition of a 25 
surfactant affected the physical stability and amorph us stability of selected model drugs.  Therefore the 26 
main objective of this study were to formulate mixed copovidone amorphous solid dispersions and 27 
compare these ASD formulations based solid-state properties, dissolution rate and solubility. 28 
Indomethacin (INM) was used as a model drug and Poloxamer 407 (P407) was used as a surfactant. Poly 29 
(vinylpyrrolidone-vinyl acetate copolymer) and Plasdone S-630 (PL-S630) in terms of monographs are 30 
the same, however they have different solid-state and dissolution properties and very little literature has 31 
been reported on hot-melt extruded quaternary mixtures and on how mixed copovidone systems using 32 
PVP VA64 and PL-S630 affect physical stability and solubility of ASDs. The ASD formulations showed 33 
a significantly higher dissolution rate compared to amorphous and pure INM in pH buffer 1.2 with a 34 
kinetic solubility of 24 µg/ml. The stability data showed that INM remained amorphous in solid solutions 35 
with PVP VA64 and Plasdone S-630, except for the higher drug loads. It was concluded that % drug 36 
loading did have a significant effect on the solubility of INM due to recrystallization at higher drug loads.  37 
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Graphical Abstract 51 
 52 
1.1. Introduction 53 
The vast majority of new chemical API’s are poorly water soluble and as a result pose many challenges 54 
for formulation scientists in pharmaceutical industries [1]. Various methods such as the formulation of 55 
pro-drugs, microization and the formulation of amorphous solid dispersions (ASDs) have been developed 56 
to overcome the solubility barrier associated with poorly water soluble drugs[2–5]. The formulation of 57 
thermodynamic high energy amorphous form of crystalline APIs is a promising method to improve the 58 
solubility of BCS class II drugs[6].  As amorphous APIs have a higher free energy, they can exhibit a 59 
dissolution rate and extent many times greater than the crystalline equivalent. However, the 60 
thermodynamic high energy amorphous form is prone to recrystallization and physically unstable[7]. 61 
Recrystallization of the API has two stages, the first step is nucleation and the second step is crystal 62 
growth[8]. Nucleation occurs at a lower temperature, while crystal growth requires significantly higher 63 
temperatures. Nucleation is the formation of small aggregates of a critical size. This is the rate-limiting 64 
step and the rate of nucleation depends on the activation energy or crystallization activation energy[9,10].  65 
Crystal growth is the diffusion of solute molecules to the surface of the nuclei or crystal lattice. Therefore 66 
preventing nucleation and crystal growth is necessary in order to prevent recrystallization and physical 67 
instability[7,8]. 68 
Recently, multi-component amorphous solid dispersions have been proposed to further improve the 69 
kinetic solubility of BCS class II drugs. A multi-component ASD, incorporating pharmaceutical 70 
excipients such as surfactants and dissolution enhancers, modifies the microenvironment of drug particles 71 















Therefore using appropriate pharmaceutical excipients can further improve the physical stability of ASDs. 73 
Quaternary (drug-polymer-polymer-surfactant) and ternary (drug-polymer-surfactant) ASDs composed of 74 
an amorphous polymer matrix, API and surfactants are considered the next step in enhancing dissolution 75 
of poorly water soluble drugs.  76 
Successful formulation of these systems requires threfore the formation of a homogenous system and 77 
physical stability must be considered [12]. It has been reported that multi-component solid dispersions 78 
such as quaternary and ternary ASDs can result in phase separation as a result of incorporating surfactants 79 
within binary and ternary ASDs [13]. Also recrystallization of an amorphized additive has been reported 80 
to retard drug release within ASDs [14]. Previous re earch has focused on spray dried quaternary 81 
mixtures which, due to the addition of a surfactant, ffected the physical stability, amorphous stability and 82 
dissolution of selected model drugs[12]. Therefore this study will focus on hot-melt extruded quaternary 83 
multi-component solid dispersions using a Poloxamer 407 (P407) as a surfactant to improve solubility of 84 
a selected model drug and prevent recrystallization. Also, ternary (drug-polymer-surfactant) ASDs will be 85 
prepared for comparison purposes.  86 
In terms of monographs, PL-S630 and PVP VA64 are the same product. However these co-polymers are 87 
manufactured from two different manufacture’s, and therefore have different solid-state and dissolution 88 
properties as a result of their manufacturing process. Differences in the manufacturing process from 89 
different suppliers of copovidone can influence the properties of the copovidone produced.  Some of these 90 
properties may be critical material attributes for the manufacturing process or performance of a drug 91 
product.  For example different supplier’s products may have different glass transition temperatures. 92 
Therefore this is why PL-S630 and PVP VA64 was chosen for this study, and very little has been reported 93 
in literature on the comparison of PL-S630 and PVP VA64 regarding their solid-state and dissolution 94 
properties.  95 
Indomethacin (INM) was selected as a model drug due it its poorly-water soluble properties. The role of 96 
drug-polymer interaction and anti-plasticization in e hancing supersaturation of INM was investigated. 97 
This is a continuation of previous work carried outto understand the interaction between INM and P407 98 
in preventing recrystallization of INM and the type of interaction between INM-PVP VA64 ASDs. The 99 
ASDs were characterized by ATR-FTIR Spectroscopy, Raman spectroscopy, X-ray powder diffraction 100 
(XRPD), phase solubility studies and in-vitro dissolution studies.  This study will aid the understanding of 101 
the use of surfactants in ASDs to aid formulation scientists in the design of multi-component amorphous 102 
















2.1 Materials and Methods 105 
2.1.1 Materials 106 
Crystalline γ-indomethacin (1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid) (INM), 107 
purchased from Tokyo Chemical Industry (TCI) (Oxford Science Park, UK) (N.V.) (Tm 160 °C Tg 42 °C), 108 
was used as a model drug[15]. INM has a kinetic solubility of 1.5 µg/ml at pH 1.2[15]. P407 (Tm 55 °C, Tg -109 
67 °C), a hydrophilic non-ionic surfactant and PVP A64 (Tm 86.16 °C, Tg 106 °C), were purchased from 110 
BASF Europe GmbH (Burgbernheim, Germany). PL-S630 (Tm 140 °C, Tg 107 °C), was received as a gift 111 
from Ashland Specialties Ltd, (UK). All other reagents and chemicals were purchased from Sigma 112 
Aldrich (Wicklow, Ireland) and were of analytical reagent grade.  113 
2.1.2 Preparation of physical mixtures 114 
8 different combinations of all four components were studied and 40 g total powder was used for each 115 
sample. Powders were weighed and mixed thoroughly in a mortar and pestle for five minutes according to 116 
the compositions detailed in Table 2 and compared against various ternary mixtures (Table 3). Also 117 
binary ASDs were using prepared using INM and P407 as a control. The % drug-polymer composition 118 
used for binary ASDs are as follows 10/90, 30/70, 5/50 and 70/30% INM-P407. Amorphous INM 119 
(aINM) was prepared by heating to 160 °C in a stainless steel beaker using a hotplate and quench cooling 120 
using liquid nitrogen.  121 
Table 2.  Batch composition used to investigate the solid-state properties and dissolution profile of 122 














Quart SD1 42.5 42.5 5 10 
Quart SD2 37.5 37.5 15 10 
Quart SD3 32.5 32.5 5 30 
Quart SD4 27.5 27.5 15 30 
Quart SD5 22.5 22.5 5 50 
Quart SD6 17.5 17.5 15 50 
Quart SD7 12.5 12.5 5 70 















Table 3. Batch composition used to investigate the solid-state properties and dissolution profile of ternary 128 
Plasdone S-630/PVP VA64 hot-melt extruded solid disper ions. 129 
 130 
2.1.3 Hot melt extrusion 131 
Hot melt extrusion was performed using a co-rotating Prism 16mm Twin-screw extruder (Thermo Fisher 132 
Scientific, USA) with a 2mm diameter die and a length to diameter (L/D) ratio of 15/1. Screws contained 133 
all-conveying elements and a screw speed of 100 RPMwas used. The extruder was split into three heating 134 
zones which, from feeding zone to the die, had set points of 140 and 160 °C. On exiting the die the 135 
extrudates was allowed to cool to 25 °C then ground er liquid nitrogen in a mortar and pestle, and 136 
passed through a 200 µm sieve to obtain an appropriately sized fraction for further studies. 137 
2.1.4 Calculation of Hansen solubility parameters (δ) and drug-polymer interaction factor (χ) 138 
Hansen solubility parameters (δ) of both the drug and polymers were calculated by considering their 139 
chemical structure orientations and their molecular weights. In order to determine drug-polymer 140 
miscibility, the solubility parameters were calculated using the combined group contribution methods of 141 
Van Krevelen-Hoftyzer and Fedors [7]. These are expressed by the following equation (Eq) 1:  142 
δ




h                      Eq. (1). 143 
Where,  144 
δd = Ʃdi  , δp =
Ʃpi2
  
1/2, δh = Ʃhi 	
1/2  145 
where i is the functional group within the molecule, δ is the total solubility parameter, δd is the 146 
contribution from dispersion forces, δp is the contribution of polar interactions, δh is the contribution of 147 
hydrogen bonding, Fdi is the molar attraction constant due to molar disper ion forces, Fpi is the molar 148 








PL-S630/PVP VA64 SD1 85 5 10 
PL-S630/PVP VA64  SD2 75 15 10 
PL-S630/PVP VA64 SD3 65 5 30 
PL-S630/PVP VA64 SD4 55 15 30 
PL-S630/PVP VA64 SD5 45 5 50 
PL-S630/PVP VA64 SD6 35 15 50 
PL-S630/PVP VA64 SD7 25 5 70 















attraction constant due to molar polarization forces, Ehi is the hydrogen bonding energy and V is the molar 149 
volume [16].  150 
The drug-polymer interaction parameter, χ, using the solubility parameters difference between the drug 151 
and polymer, can be estimated by a method developed by Hildebrand and Scott [17]. 152 




	 (δdrug – δpolymer)
2          Eq. (2). 154 
where Vo is the volume of the lattice site, R is the gas constant and T is the absolute temperature. 155 
2.1.5 ATR-FTIR Spectroscopy 156 
ATR-FTIR spectra were collected using a Perkin Elmer, Spectrum One fitted with a universal ATR 157 
sampling accessory. Data was collected in the spectral range of 4000-420cm−1, utilizing a 16 scan per 158 
sample cycle and a fixed universal compression force f 80N. Subsequent analysis was carried out using 159 
Spectrum software. 160 
2.1.6 Raman Spectroscopy 161 
Raman spectra were obtained using a Reninshaw invia Raman confocal microscope (Renishaw 162 
Instruments, Gloucestershire, UK) coupled to a motorised stage. Raman scattered light from a 785 nm 163 
laser, operating at 300 Mw using 100% laser power. Spectra were collected between 100 and 3200 cm-1,164 
and with a total collection (acquisition) time of 10 seconds. The lens used was a x20 lens, with a laser 165 
spot size of 50 µm. The beam path grating used was 1200 l/mm (633/780).  166 
2.1.7 X-ray powder diffraction (XRPD) 167 
X-ray diffraction spectra were collected using a Philips PANalytical X’Pert MPD Pro with PW3064 168 
sample spinner. The dried granules were gently ground using a pestle and mortar and placed on zero-169 
background silica disks. The diffraction pattern was collected between 5 and 40° (2θ) with a step size of 170 
0.0167°, a counting time of 29.845 s, and a sample rotation of 15 rpm using PANalytical Data Collector, 171 
version 2.0. The source was Cu Kα (λ = 1.5418 Å), the accelerating voltage was 40 kV, and the anode 172 
current was 35 mA. A fixed divergence slit of ¼” and a 0.020 mm nickel filter were used 173 
2.1.8 Phase solubility Studies 174 
Solubility studies of pure drug and polymers were performed in triplicate using the method reported by 175 
Higuchi and Connors (Higuchi et al. 1965) in pH buffer 1.2[18]. An excess amount of INM was added to 176 















volumetric flasks. The suspensions were maintained at 37 °C for 24 h. This duration was previously 178 
tested to be sufficient to reach equilibrium. 179 
2ml aliquots were withdrawn and were filtered through 25mm Millex - LCR PTFE hydrophilic syringe 180 
filters (0.45 µm, Merck Millipore LTD, Ireland). The filtrates were suitably diluted if required and 181 
analyzed, spectrophotometrically for the dissolved drug at 320 nm. Shaking was continued until three 182 
consecutive readings were performed. The apparent 1:1 stability constant Ka was calculated from the 183 




                               Eq. (2). 185 
Where So is the intrinsic aqueous solubility of INM.  The Gibbs free energy of transfer (∆G 0) of INM 186 
from pure water to the aqueous solution of carrier was calculated by the equation below. 187 
∆G 0 = -2.303 RT log So/Ss        Eq. (3).   188 
where SO/SS is the ratio of molar solubility of INM in aqueous solutions of carrier to that of the same 189 
medium without carrier. 190 
Also the solubility of the various ASD formulations and physical mixtures were performed in pH buffer 191 
1.2. An excess amount of ASD formulation was mixed with 10ml of pH buffer 1.2 and was shaken at 37 192 
°C in a mechanical shaker for 24 hours. 2ml aliquots were withdrawn and were filtered through 25mm 193 
Millex - LCR PTFE hydrophilic syringe filters (0.45 µm, Merck Millipore LTD, Ireland). The filtrates 194 
were suitably diluted if required and analyzed, spectrophotometrically for the dissolved drug at 320 nm as 195 
previously mentioned.   196 
2.1.9 In-Vitro Dissolution Studies 197 
The release rate of INM from ASDs was determined uner non-sink conditions using United States 198 
Pharmacopeia (USP) dissolution testing apparatus 1 (basket method) (Distek 50947, USA) with a paddle 199 
speed of 50 rpm. The dissolution test was performed using 900 ml of pH buffer 1.2 at a temperature of 37 200 
± 0.5 °C.  A formulation equivalent to 100 mg of INM in ASDs were placed in dissolution medium, with 201 
5 ml aliquots withdrawn at predetermined time intervals (0, 10, 17, 24, 45 minutes and 1, 2 and 3 hours), 202 
and filtered through a 25mm Millex - LCR PTFE hydrophilic syringe filter (0.45 µm, Merck Millipore 203 















The concentration of INM in each sample was determined using a UV-1280 UV-Vis spectrophotometer 205 
(Shimadzu, Japan) and a standard calibration curve. Fresh dissolution medium was used as a blank. Pure 206 
INM and amorphous INM were used as controls. The concentration of INM dissolved for each 207 
formulation (n =3) was plotted as a function of dissolution time with data being expressed as the average 208 
± standard deviation of replicate absorbance measurments. 209 
2.1.10 Statistical Analysis 210 
The drug dissolution profiles of all ASD formulations were compared using an analysis of variance 211 
(ANOVA) statistical test. The impact of the amorphous form on the area under the curve (AUC) was 212 
statistically examined using (ANOVA) (GraphPad Prism version 5.03 for Windows, GraphPad Software, 213 
San Diego, CA). Post-hoc comparisons of the means were performed using Tukey’s Multiple Comparison 214 
test. A significance level of * p < 0.05 was accepted to denote significance in all cases. 215 
 216 
2.1.11 Accelerated amorphous stability studies 217 
Stability studies were conducted under accelerated conditions (40 °C, 75% relative humidity) for 5 218 
months by placing ASDs in open glass vials which were stored in a desiccator which contained a 219 
saturated solution of sodium chloride to generate a r l tive humidity of 75% RH. The relative humidity 220 
inside the desiccator was checked regularly using a thermohygrometer. The stored ASDs were dried over 221 
phosphorus pentoxuide for at least 24 hours prior to hyper analysis to remove the significant moisture 222 
endotherm exhibited in non-dried samples. 223 
Hyper DSC studies were conducted on a PerkinElmer DSC 8500 equipped with a refrigerated cooling 224 
accessory (PerkinElmer, UK). Helium, 30 mL/min, was used as purge gas. The instrument was calibrated 225 
using a heating rate of 100 °C/min using high purity indium to standardize the temperature and heat flow 226 
signal. Then 1.0−2.5 mg samples were weighed and placed in crimped DSC pans. Samples were ramped 227 
from -10 to 180 °C at 100 °C/min. The analysis was c rried out using PerkinElmer Pyris Thermal 228 
Analysis software, version 10.1 and any numerical vlues reported are the average ± SD of three 229 



















3.1 Results and Discussion 235 
3.1.1 Hansen solubility parameters (δ) and drug-polymer interaction factor (χ) 236 




Based upon their chemical structures, the Hansen solubility parameters (δ) for INM, PVP VA64, PL- 241 
S630 and P407 were calculated to be 23.00 MPa1/2, 26.40 MPa1/2, 26.40 MPa1/2 and 25.50 MPa1/2 242 
respectively. Recent literature has reported that favourable intermolecular interactions and a uniform 243 
phase will result if the difference in the δ values between each of the components (∆δ) is less than 7 244 
MPa1/2  as shown in Table 5, while unfavourable intermolecular interactions and phase separation and/or 245 
recrystallization will result if ∆δ > 7 MPa1/2 [19]. In this study, ∆δ between all polymers and INM was 246 
less than 7 MPa1/2 and in theory are likely to be miscible. 247 
In this study the Hildebrand-Scott method was used and is the theoretical method applied to determine F-248 
H interaction parameters and is based on the Hansen solubility parameters developed by Van Krevelen 249 
and Hoftyzer group contribution. The value of χ, refers to the square of the difference in solubility 250 
parameters calculated by Van Krevelen and Hoftyzer group contribution method at 25 °C. A numerical 251 
value close to zero of χ shows favourable intermolecular interactions with drug-polymer ASD systems 252 
[17]. This was the case as all values were close to zer  and miscibility between INM, PVP VA64, PL-253 
S630 and P407 is very likely to be in the following order (PVP VA64/PL-S630>P407>INM) as shown in 254 
Table 4. It is important to note that the Hansen solubility parameters and F-H interaction parameters are 255 
only theoretical and drug-polymer miscibility between INM and polymers was further examined using 256 
ATR-FTIR spectroscopy, Raman spectroscopy, XRPD, phase solubility studies, in-vitro dissolution 257 
studies and accelerated stability studies in conjunctio  with MDSC. 258 
 259 
Compound δt (MPa
1/2) ∆δ (MPa1/2) χ 
INM 23.00 - - 
PVP VA64 26.40 3.40 0.46 
PL-S630  26.40 3.40 0.46 

















3.1.2  ATR-FTIR Spectroscopic Studies 262 
 263 
 264 
Figure 1. a) ATR-FTIR Spectra of pure components and selected ASD formulations (30% INM). b) 265 
ATR-FTIR Spectra of both PVP VA64/PL-S630 and SD1/SD2 indicating potential hydrogen bonding due 266 
to the shift in the amide carbonyl of both PVP VA64 and PL-S630 from 1672 cm-1 to 1685 cm-1 . There is 267 
no shift in the vinyl acetate carbonyl peak as a result of its weaker hydrogen bond potential. (c) ATR-268 
FTIR spectra of binary ASDs of 10 and 30% INM-P407 drug-polymer mixtures.  269 
ATR-FTIR spectroscopy was used to examine the intermolecular interactions for the all ASD 270 
formulations and to confirm the amorphous or crystalline nature of the API within the ASD formulations. 271 
Crystalline INM was characterized by principal absorpti n peaks and showed two strong C=O bands at 272 















which are non-hydrogen bonding (Fig.1). The hydrogen-bonded O-H stretch of the acid is shown in 274 
Figure 1 is superimposed on the sharp C-H stretches, as recent literature has shown that the free 275 
carboxylic acid O-H stretch can exist as dimers due to hydrogen bonding[15]. PVP VA64 and PL-S630 276 
had two strong principal peaks at 1731.00 cm-1 (C=O stretch of the vinyl acetate) and 1672.00 cm-1 277 
(amide carbonyl C=O stretch) as shown in Figure 1 (b). In the ATR-FTIR of aINM, the above named 278 
peaks shifted to 1707.00 cm-1 and 1679.00 cm-1 respectively due to conversion to its amorphous form as 279 
shown in Figure 1.  280 
The ATR-FTIR of all the ASD formulations with PL-S630, PVP VA64 and P407, amorphous INM was 281 
present and there evidence of intermolecular interac ion i.e. hydrogen bonding due to the shift of the282 
amide carbonyl of PVP VA64/PL-S630 from 1672.00 cm-1 to 1680 cm-1 (Fig.2) and (Fig. 1 (b)). There 283 
was no shift observed in the C=O of the vinyl acetate carbonyl of PVP VA64/PL-S630 in the ATR-FTIR 284 
spectra, however in the Raman spectra it must be noted that there was a shift in the vinyl acetate C=O 285 
carbonyl in the all ASD formulations, however they quaternary ASD formulations had the greatest shift as 286 
shown in Figure 4. This is very significant as most literature states that they vinyl acetate C=O carbonyl is 287 
a weak hydrogen bond acceptor which was reported by Yuan et al. (2015) [20]. Any poloxamer peaks 288 
present in the pure P407 sample were not present in the ATR-FTIR spectra of the SD formulations as 289 
shown in Figure 1 (c). This may indicate that P407 possibly has no molecular interaction with INM [21]. 290 
 291 
Figure 2. ATR-FTIR Spectra of a selected ASD formulation (Quart SD2) illustrating the hydrogen bond 292 
between PVP VA64/PL-S630 and INM due to the shift in the amide carbonyl of both PVP VA64 and PL-293 
S630 from 1672 cm-1 to 1685 cm-1. 294 















Raman analyses was carried out to explore the interactions between INM, PVP VA64, P407 and PL-S630 296 
in the multi-component solid dispersions prepared by the HME process. Raman spectroscopy is 297 
complimentary to ATR-FTIR spectroscopy, and it is quite useful for the analysis of ASDs. API’s 298 
normally tend to be conjugated or aromatic compounds which have strong Raman signals, while 299 
excipients have much weaker Raman signals and/or spectra. Similar to the ATR-FTIR studies, Raman 300 
spectroscopy showed potential intermolecular interac ion between INM and polymeric carriers due to a 301 
shift in the amide carbonyl of PVP VA64 and PL-S630. The PVP VA64 amide carbonyl (vC=O) peak at 302 
1673.00 cm-1 shifted to 1680.00 cm-1 in ASD samples due to hydrogen bonding interaction with the –OH 303 
group of INM as a result of hot melt extrusion as shown in Figure 3. The acid vC=O present at 1702.00 304 
cm-1 (free C=O of carboxylic acid) of INM completely disappears in the Raman spectra of the ternary and 305 
quaternary ASD formulations as a result of hydrogen bo ding. It must be noted even though a hydrogen 306 
bond shift was observed in all ASD formulations, the quaternary ASD formulations had a much greater 307 
shift as a result of the mixed copovidone present in he quaternary mixtures as shown in Figure 4. 308 
However small differences in the intensity and shift  in the peak positions were observed as a result of the 309 
HME process in the region of carbonyl group peaks (1660–1670 cm−1). In summary, the ATR-FTIR and 310 
Raman analyses suggest that similar hydrogen bonding interactions were achieved in solid dispersions 311 
prepared by the HME process (Fig. 3). The Raman analysis confirmed the ATR-FTIR results indicating 312 
hydrogen bonding interaction occurred between INM and PVP VA64/Plasdone S-630 as expected.  313 
 314 
Figure 3. Raman spectra of pure components and selected ASD formulations (30% INM), indicating 315 
potential hydrogen bonding due to the shift in the amide carbonyl of both PVP VA64 and PL-S630 from 316 




















Figure 3. Raman spectra of selected quaternary and ternary ASD formulations (30% INM), indicating 323 
potential hydrogen bonding due to the shift in the amide carbonyl and vinyl acetate carbonyl of both PVP 324 
VA64 and PL-S630 from 1673 cm-1 to 1680 cm-1 . The vinyl acetate carbonyl appears at a low intensi y 325 
between 1732.00 and 1768.00 cm-1.    326 
3.1.4 XRPD Studies 327 
The physical state of pure and amorphous INM, pure P407, pure PVP VA64/PL-S630 and ASD 328 
formulations were further examined by XRPD analysis. The XRPD patterns of pure drug, polymers and 329 
ASD formulations are shown in Figures 5(a) and 5(b). XRPD pattern for pure INM had several diffraction 330 
peaks due to the crystalline nature of the drug. The main principal crystalline peaks occurred at diffraction 331 
angles (2θ) at 11.72°, 17.11°, 19.67°, 20.93°, 21.90°, 24.03°, 26.64° and 29.43° as shown in Figure 5(a). 332 
These values were similar to the values reported in literature for this drug[22]. The XRPD pattern of PVP 333 
VA64 and PL-S630 were amorphous in nature.  This can be a seen by a slight amorphous halo raised 334 
above the baseline. P407 which is semi-crystalline in nature contained two strong principal diffraction 335 















XRPD analysis of the ASD formulations confirmed the amorphous nature of INM within all ASD 337 
formulations due to the slight halo raised above the baseline, due to the lack of any sharp, well-defined 338 
peaks in the diffractograms as shown in Figure 5 (b). However, the 50% and 70% INM SD formulations 339 
were not completely amorphous due to the high INM loading as expected.  340 
For all other SD formulations both ternary and quaternary ASDs, the semi-crystalline peaks associated 341 
with P407 was present, compared to the SD formulations reported by Gumaste et al.(2016)[23] in which 342 
poloxamer was converted to its amorphous form. However in the XRPD diffractograms of the 5% P407 343 
loading ASD formulations, the semi-crystalline peaks of P407 appear at much weaker intensity compared 344 
to the 15% P407 loading samples. This may be due to the fact that the physical interaction from P407 is 345 
much greater at high poloxamer loadings.  346 
 347 
Figure 5. a) XRPD diffractograms of the pure components and (b) XRPD diffractograms of selected ASD 348 
formulations indicating that the INM is present in he amorphous form, but the P407 is not solubilized an  349 
due to its semi-crystalline nature exists in its semi-crystalline form. The 70% INM ASD formulations 350 
remained crystalline. 351 
3.1.5 Phase Solubility Studies 352 
INM shows a pH dependent solubility and is a weak acid with a pKa of 4.5. As the pH increases the 353 
kinetic solubility of INM increases. Pure INM shows a solubility of 1.5 µg/ml in pH 1.2[15]. PVP VA64 354 

















studies were performed in pH buffer 1.2. The kinetic solubility of INM from the various quaternary ASD 356 
formulations are shown in Table 6. Also, a phase solubility plot of solubility of INM (µg/ml) against 357 
polymer concentration (% w/v) was drawn and exhibited a linear relationship in the chosen polymer 358 
concentration range that was examined. With regards to Figure 6, the Gibbs free energy values decreased 359 
as the % polymeric carrier loading decreased as shown in Table 5, which indicates that the drug 360 
solubilization process was indeed spontaneous[24].  361 
Table 5. Gibbs free energy Values and Apparent stability constants (Ka) of ternary and quaternary drug-362 
polymer-surfactant interactions.  363 
 364 
 365 
The entropy of mixing is always favoured and thus negative for drug-polymer ASD mixtures. The phase 366 
solubility plot shown in Figure 6 was an A-type phase solubility profile which shows that the kinetic 367 
solubility of INM increases with increasing polymer concentration. When a complex is first-order in 368 
nature with respect to ligand (polymeric carrier) and linear with respect to the substrate (API), hence the 369 
AL-type phase solubility curve is obtained[25]. For the ASD formulations, after 24 hours the quaternary 370 
ASD formulations had the highest kinetic solubility with a value of 76.30 µg/ml (Quart SD1) with 10% 371 
INM loading as shown in Table 4. The physical mixtures with the exception of PVP VA64 SD1, PL-S630 372 
SD1 and Quart SD1 had a greater solubility for INM compared to the ASD formulations. This may have 373 
been due to recrystallization of INM due to high loading of P407 in the ASD formulations.  374 
This is a significant improvement in the solubility of INM compared to the solubility reported by Chokshi 375 
et al. (2008) who reported that the maximum solubility of INM achieved after 24 and 72 hours was 376 
10µg/ml and 30 µg/ml respectively, using 30, 50 and70% INM loading. It also has been reported in 377 
Concentration 














of Polymer (% 
wt/vol) 






5 5 5 50 5 1.56 0.58 0.23 
7.5 25 25 50 25 -1.37 -1.07 -0.94 
10 45 45 50 45 -2.27 -1.87 -1.63 
12.5 65 65 50 65 -2.64 -2.57 -2.35 
15 85 85 50 85 -3.78 -2.72 -2.56 
 Intercept  1.90 x 100 5.42 x 100      5.96 x 100 
 Slope  0.30 x 100 0.19 x 100      0.16 x 100 















literature that high poloxamer loading at high drug loads can retard drug release as a result of the gelling 378 
properties of poloxamer at high drug concentrations. Physical mixtures tend to have a higher solubility 379 
because when the drug-polymer mixtures in the dry state are dispersed in aqueous solutions of polymer, 380 
polymeric particles hydrate rapidly due hydrophilic nature of P407 within polymer solutions resulting  381 
the increased wettability of the drug particles[21]. This is related to surface activity and wetting effect 382 
which results in reduced agglomeration and solubilizing effect of P407. The kinetic solubility of the 383 
mixed PVP VA64 and PL-S630 systems was significantly higher than the ternary systems (Table 6), this 384 
may be due to greater vinyl acetate hydrogen bonding interaction as shown in Figure 4 in quaternary ASD 385 
formulations.  386 
Table 6. Comparison of the solubility of INM from various quaternary and ternary ASD formulations and 387 
corresponding physical mixtures in pH buffer 1.2 after 3 and 24 hours respectively.  388 
Formulation Solubility of INM (µg/ml) after 3 hrs. Solubility of INM (µg/ml) after 24 hrs. 
ASD Physical Mixture ASD 
PVP VA64 SD1 4.43 4.57 11.20 
PVP VA64 SD2 7.90 21.23 5.67 
PVP VA64 SD3 7.80 21.93 4.00 
PVP VA64 SD4 20.73 26.50 2.13 
PVP VA64 SD5 6.86 29.17 1.50 
PVP VA64 SD6 9.20 19.77 4.17 
PVP VA64 SD7 1.33 18.83 0.93 
PVP VA64 SD8 6.47 16.23 6.73 
PL-S630 SD1 13.83 4.40 14.00 
PL-S630 SD2 14.03 14.80 14.00 
PL-S630 SD3 8.40 7.77 6.43 
PL-S630 SD4 10.60 11.57 10.60 
PL-S630 SD5 0.50 7.63 4.37 
PL-S630 SD6 3.37 6.70 8.07 
PL-S630 SD7 2.03 7.27 6.90 
PL-S630 SD8 2.83 7.13 4.50 
Quart SD1 6.40 53.87 73.60 
Quart SD2 12.67 45.63 31.23 
Quart SD3 5.50 26.13 23.47 
Quart SD4 8.03 24.30 34.17 
Quart SD5 4.30 29.00 16.77 
Quart SD6 4.87 22.57 14.13 
Quart SD7 9.43 20.23 16.53 


















Figure 6. Solubility of INM (µg/ml) in aqueous solutions of PL-S630, PVP VA64 and P407 at 37°C 392 
(each point represents the average + SD of 3 independently prepared ASD samples) with a maximum 393 
kinetic solubility of 34 µg/ml.  394 
3.1.6 In-vitro dissolution studies 395 
To further understand how the intermolecular interactions within multi-component i.e. quarternary and 396 
ternary ASDs affect the INM dissolution profile in pH buffer 1.2, in-vitro dissolution experiments were 397 
performed under non-sink conditions. The aim of this study was to examine the synergistic effect of the 398 
various polymer combinations within ASDs and how it affected the maintenance of INM supersaturation. 399 
Pure INM and amorphous INM were also used as a control. The area under the curve (AUC) was 400 
calculated as a measure of the length of time that the supersaturated concentration could be maintained or 401 
achieved i.e. a measure of the supersaturated concentration[26]. The AUC was used to compare the 402 
solubility of INM between selected ASD formulations and pure/amorphous INM. Particle size was 403 
controlled in this study, the initial drug dosage within the dissolution vessels was 100mg as the particle 404 
size of each formulation was 200 microns as they were sieved prior to analysis.  405 
Pina et al. (2014) proposed dissolution that is carrier contrlled through their work with both completely 406 
and partially controlled amorphous dispersions[27]. It was observed that the type of polymer used had a 407 
significant effect on the dissolution compared to the morphology of the drug, partially crystalline 408 















therefore they proposed a controlled carrier mechanism. The drug release curves however in this study di  410 
not exhibit the spring and parachute effect, however th y showed an increase in the drug concentration 411 
over 3 hours of dissolution. However it must be noted that a spring and parachute effect can still as ASDs 412 
readily show a ‘’spring’’ and the parachute effect, may however be a slow parachute with supersaturation 413 
sustaining for many hours before precipitation start  to occur to define the parachute phase. It must be 414 
noted that all ASD formulations did not completely dissolve over the entire duration of the dissolution 415 
study. Therefore it is assumed that neither the polymer nor the drug completely dissolves over the 3 hours 416 
in pH buffer 1.2. Potter et al. (2015) prepared ASDs containing 10, 30 and 50% INM via spray drying and 417 
hot melt extrusion and reported that polymer and INM did not completely dissolve even after 8 hours of 418 
dissolution[26].  419 
The kinetic solubility of all ASD formulations increased compared to pure and amorphous INM (Fig.7). 420 
Amorphous and crystalline INM had a kinetic solubility of 2.4 µg/ml and 1.2 µg/ml as expected due to its 421 
conversion to the amorphous form. The increase in the kinetic solubility of INM was dependent upon 422 
both surfactant and polymeric carrier loading. The kinetic solubility of INM in this study increased by at 423 
least 10 times over 3 hours. Chokshi et al. (2008) prepared binary drug-polymer mixtures of PVP-VA64-424 
INM and achieved a maximum kinetic solubility of 10µg/ml for all solid dispersions prepared using 70, 425 
50 and 30% INM in pH buffer 1.2[22]. It was also a significant improvement compared to the kinetic 426 
solubility of INM reported by Potter et al. (2015)[26] who prepared binary mixtures of INM and PVP via 427 
hot melt extrusion and spray drying and achieved a maximum kinetic solubility of 8 µg/ml.   428 
There was very little difference in terms of solubiity between both the ternary ASD formulations and 429 
quaternary ASD formulations after 3 hours as shown in Figure 6. In this study PVP VA64 had the highest 430 
kinetic solubility with a value of 20.73 µg/ml (PVP VA64-SD4 (30% INM)) after 3 hours of dissolution. 431 
This was a similar result to the solubility from the previous study where the maximum solubility reported 432 
was 20 µg/ml with a 25% drug loading[28]. The ASDs with highest poloxamer loading had the highest 433 
solubility after 3 hours, this was due to the hydroph bic P407 propylene oxide core of the micelle which 434 
incorporated into the INM water-insoluble molecules. P407 exists as a unimer self-assembled into 435 
micelles in solution [29]. This may have resulted in the increased kinetic solubility of INM molecules. 436 
P407 results in greater wetting and increases the surface that is available by reducing the interfacial 437 
















Figure 7. In-vitro dissolution profiles of quaternary ASDs and graphical representations of AUC of 440 
quaternary and ternary ASD formulations in pH 1.2. ** and * represents the statistical difference (p < 441 
0.05) between ASD, amorphous INM and pure INM respectiv ly, for 1-way ANOVA and Tukey Kramer 442 
post hoc test.  443 
The AUC values of all ASD formulations was compared with pure and amorphous INM using a 1-way 444 
ANOVA and Tukey Kramer post hoc test (Figure 7). For b th the quarternary, PL-S630 and PVP VA64 445 
ternary ASD formulations with the exception of Quart SD2, Quart SD4, Quart SD7, Quart SD8, PVP 446 
VA64 SD2, PVP VA64 SD4, PL-S630 SD1, PL-S630 SD2 and PL-S630 SD4 there was no statistical 447 
difference between crystalline and amorphous INM. The overall effect of drug and % wt of poloxamer 448 
did have a significant effect on the solubility of INM and AUC in solution. After 3 hours, the ASD 449 
formulations did have a higher kinetic solubility compared to the pure and amorphous drug due to the 450 
conversion to the amorphous form (Fig. 7). For the quarternary mixtures only all ASDs with the highest 451 
% of poloxamer loading recrystallized with the exception of Quart SD4 and Quart SD8 as previously 452 

















3.1.7  Accelerated stability studies 456 
The 8 different combinations of ASD formulations were subjected to accelerated conditions of 40°C and 457 
75% RH for 5 months, after which hyper DSC was performed to investigate the amorphous stability and 458 
to examine the crystalline content of each of the formulations as shown in Figure 8. Sinclair et al. (2011) 459 
reported the relative instability of all ASD formulations as a result of moisture uptake due to PVP which 460 
is very hygroscopic in nature [30]. It has been well documented in literature that water can act as a 461 
plasticizer and as a result lower the Tg of ASD formulations enhancing the molecular mobility of drugs 462 
and polymers. Therefore prior to hyper DSC analysis all moisture was removed by drying the samples in 463 
a desiccator for 24 hours using phosphorus pentoxide as a desiccant.  464 
The samples were dried as the moisture was coming off at the same temperature that the Tg occurred. 465 
After 5 months, all melt extrudates of the drug with PVP VA64, PL-S630 and P407 remained amorphous 466 
except for the 50% and 70% ASD formulations and showed no depression in Tg as a result of the moisture 467 
being removed compared to the initial Tg. This was also the case for Hurley t al. (2018) where ASDs 468 
were prepared with PVP VA64, P407 using INM as a model drug. All ASDs remained amorphous and 469 
showed no depression in Tg after 5 months stability. A single Tg was obtained for all formulations which 470 
is shown in Figure 8. It must be noted that a single Tg in ASD formulations may not be an indicator of a 471 
non-heterogeneous system. Qian et al. (2010) who reported may not always be a reliable indicator of 472 
homogeneity and optimal stability. Qian et al. (2010) prepared two batches of ASDs using PVP VA64 473 
and BMS-A as polymeric carriers and although two batches contained a distinctive single Tg, they 474 
exhibited crystallization and physical stability overtime [31].   475 
The higher drug load ASD formulations recrystallized as a result of the high drug loading as expected, 476 
however as for the lower drug loads the drug remained amorphous which was similar to the data reported 477 
previously by Hurley et al. (2018)[28]. Hurley et al. (2018) prepared 5%, 10%, 15%, 20% and 25% INM 478 
ASD formulations and all ASD formulations remained amorphous and % P407 loading had no effect on 479 
















Figure 8. Hyper DSC traces of ASD formulations after 5 months stability study under accelerated aging 482 
conditions of 40°C and 75% RH. The heating rate used was 100°C/min. The area of interest of the γ-INM 483 
melting endotherm is marked by solid lines.  484 
4.1 Conclusion 485 
The addition of polymer combinations and surfactants such as P407 had a significant effect on the solid-486 
state and dissolution properties of INM. P407, when incorporated into ASDs, reduced stability and 487 
resulted in altered dissolution rates. Drug loading also had a significant effect with high drug loadings 488 
resulting in recrystallization of INM. XRPD confirmed that INM was successfully converted into the 489 
amorphous form via the hot melt extrusion process except for the 50% and 70% ASD formulations which 490 
remained crystalline. Both ATR-FTIR and Raman spectros opy confirmed hydrogen bonding between the 491 
–OH group of the carboxylic acid of INM and the amide carbonyl of PVP VA64/PL-S630. It was 492 
observed that when Raman spectroscopy was performed, th re was a shift in the vinyl acetate C=O 493 
carbonyl in the all ASD formulations, however they quaternary ASD formulations had the greatest shift. 494 
This is very significant as it was reported by Yuan et al. (2015) that vinyl acetate C=O carbonyl is a weak 495 
hydrogen bond acceptor 496 
Phase solubility studies of INM in aqueous solutions of PVP VA64, PL-S630 and P407 showed an 497 
increase in the kinetic solubility of INM compared to pure drug at 37°C in pH buffer 1.2 with a maximum 498 















The ASD formulations showed a significantly higher dissolution rate compared to amorphous and pure 500 
INM in pH buffer 1.2 with a kinetic solubility of 24 µg/ml after 3 hours. After performing phase 501 
solubility studies for 24 hours on all ASD formulations, the maximum kinetic solubility reported was 502 
73.60 µg/ml.  503 
This is very significant compared to values reported via Potter et al.(2015) and Chokshi et al. (2008) was 504 
8µg/ml, 10 µg/ml and 30 µg/ml after 8, 24 and 72 hours respectively prepared via hot melt extrusion and 505 
spray drying[22],[26]. The kinetic solubility of the mixed PVP VA64 and PL-S630 systems was 506 
significantly higher than the ternary systems due to greater vinyl acetate hydrogen bonding interaction in 507 
the mixed copovidone blends.  508 
The stability data showed that INM remained amorphous in solid solutions with PVP VA64 and PL-S630 509 
except for the 50% and 70% INM ASD formulations, therefore % drug loading did have a significant 510 
effect on the amorphous stability of INM resulting in recrystallization for the higher drug loads. This 511 
work illustrates the significance of utilizing quarternary and ternary drug-polymer intermolecular 512 
interactions by incorporating polymers with different crystallization inhibition mechanisms for to improve 513 
solid-state properties, dissolution properties and morphous stability of BCS class II drugs such as INM. 514 
Also it also illustrates that mixed copovidone systems have a significant effect on the dissolution 515 
properties of INM. So utilizing mixed copovidone systems in SD formulations, to improve the kinetic 516 
solubility of INM, formulation scientists have to carefully examine the effect of solid-state properties and 517 
dissolution properties on the solubility of BCS class II drugs.  518 
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